Illumina, Inc. (NASDAQ:ILMN) Shares Bought by LPL Financial LLC

LPL Financial LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 24.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 82,867 shares of the life sciences company's stock after acquiring an additional 16,339 shares during the period. LPL Financial LLC owned about 0.05% of Illumina worth $11,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. Bleakley Financial Group LLC purchased a new stake in Illumina in the 4th quarter worth approximately $751,000. Zacks Investment Management purchased a new stake in shares of Illumina in the third quarter worth $2,924,000. Van ECK Associates Corp raised its position in shares of Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after purchasing an additional 22,718 shares during the period. Strategic Financial Concepts LLC bought a new position in Illumina in the 4th quarter worth approximately $1,464,000. Finally, Allworth Financial LP increased its holdings in shares of Illumina by 720.7% in the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock worth $1,001,000 after purchasing an additional 6,263 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Down 4.3 %

Shares of ILMN traded down $3.15 during mid-day trading on Tuesday, hitting $70.30. 3,213,335 shares of the company traded hands, compared to its average volume of 2,242,774. The company has a market capitalization of $11.14 billion, a PE ratio of -9.15, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average of $93.03 and a 200 day moving average of $123.78. Illumina, Inc. has a 1-year low of $69.38 and a 1-year high of $156.66.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research reports. Royal Bank of Canada lowered their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday. Robert W. Baird decreased their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. TD Cowen downgraded Illumina from a "buy" rating to a "hold" rating and decreased their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Citigroup cut their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday. Finally, Stephens reiterated an "overweight" rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $139.85.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.